Friday 6 November 2026
Export JAZZ’s income statement to Excel — free account
Jazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
235.25
7.93
+3.49%
Follow JAZZ
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 7 | 6 | 5 |
+8 more TTM periods Free account |
| 5.05% | 22.11% | 0.68% | (8.47%) | ||
| 1.76% | 8.54% | 0.25% | (3.01%) | ||
ROIC |
3.86% | 8.06% | (0.34%) | (3.72%) | |
Return on Tangible Assets |
8.94% | 48.26% | 1.16% | (16.77%) | |
Average Days of Receivables |
67.59 | 69.88 | 68.77 | 71.05 | |
Free Cash Flow per Share |
10.27 | 22.41 | 5.07 | 5.18 | |
Free Cash Flow |
664.54 | 1,416.54 | 313.74 | 316.14 | |
Capital Expenditures |
(1,027.94) | (244.54) | (1,020.44) | (1,039.64) | |
| Other line items | |||||
Cash ROIC |
5.27% | 12.48% | 2.46% | 2.61% | |
Accounts Receivable Turnover |
5.76 | 5.77 | 5.96 | 5.52 | |
Accounts Payable Turnover |
1.93 | 4.89 | 5.44 | 5.03 | |
Inventory Turnover |
1.10 | 1.12 | 1.15 | 1.12 | |
Average Days of Payables |
269.74 | 88.01 | 68.51 | 88.55 | |
Days of Inventory on Hand |
322.02 | 303.43 | 299.72 | 302.42 | |
Tax Rate |
(0.21) | 0.29 | (1.14) | (0.43) | |
Research and Development Expense of Revenue |
17.58% | 17.73% | 17.98% | 18.34% | |
Selling, General and Administrative Expense of Revenue |
32.98% | 36.48% | 37.13% | 42.40% | |
Share Based Compensation of Revenue |
6.27% | 6.67% | 6.71% | 6.82% | |
Interest Coverage |
2.54 | 5.25 | (0.21) | (2.21) | |
Operating CF/Net income |
8.22 | 1.77 | 45.30 | (3.81) | |
Depreciation/Fixed assets |
3.20 | 3.39 | 3.51 | 3.48 | |
Capex/Depreciation |
(1.43) | (0.34) | (1.43) | (1.49) | |
Revenue per Share |
72.92 | 72.81 | 71.71 | 69.98 | |
Operating CF per Share |
26.16 | 26.28 | 21.55 | 22.23 | |
Capex per Share |
(15.89) | (3.87) | (16.49) | (17.05) | |
Capex to Sales |
0.22 | 0.05 | 0.23 | 0.24 |
Columns are period end dates · fundamentals updated 5 Nov 2026